References

1. Gitlin N. The liver biology and pathobiology, 4th edition: Irwin M. Arias, James L. Boyer, Frances V. Chisari, Nelson Fausto, David Schachter, and David A. Schafritz. 1088 pp. $249.00. Lippincott Williams and Wilkins, Philadelphia, Pennsylvania, 2001. ISBN 0-7817-2390-6. Web address for ordering: www.lww.com. Gastroenterology 2003;125:1909-10.
2. Küthe F. Over de functie van de lever. Ned Tijfschr Geneeskd 1860:583-603.
3. Oude Elferink RP, Kwekkeboom J. Leverziekten. Hoofdstuk 4: Functies van de lever. Springer 2009:25-34.
4. Elzas M. De ziekten der spijsverteringsorganen, voornamelijk met het oog op de behandeling. Aanwinsten op diagnostisch en therapeutisch gebied 1933:358-69.
5. Bataller R, Brenner DA. Liver fibrosis. The Journal of clinical investigation 2005;115:209-18.
6. Koehler EM, Schouten JN, Hansen BE, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. Journal of hepatology 2012;57:1305-11.
7. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. Journal of hepatology 2019;70:151-71.
8. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014;12:145.
9. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012;380:2095-128.
10. Clain DJ, Lefkowitch JH. Fatty liver disease in morbid obesity. Gastroenterology clinics of North America 1987;16:239-52.
11. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409-15.
12. Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34.
13. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. Jama 2015;313:2263-73.
14. WHO. Global status report on alcohol and health 2018. 2018.
15. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-8.
16. WHO. Global hepatitis report 2017. 2017.
17. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908-22.
18. Nobili V, Mantovani A, Cianfarani S, et al. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. Journal of hepatology 2019;71:802-10.
19. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Seminars in liver disease 2012;32:3-13.
20. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology 2015;13:643-54.e9.
21. Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of hepatology 2017;67:1265-73.
22. Pais R, Barritt ASt, Calmus Y, et al. NAFLD and liver transplantation: Current burden and expected challenges. Journal of hepatology 2016;65:1245-57.

23. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547-55.
24. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. Journal of hepatology 2015;62:1148-55.
25. Kim G-A, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. Journal of hepatology 2018;68:140-6.
26. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2016;14:124-31.e1.
27. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45.
28. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
29. Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol 2010;105:336-44.
30. Ma J, Hwang SJ, Pedley A, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. Journal of hepatology 2017;66:390-7.
31. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014;146:726-35.
32. BasuRay S, Smagris E, Cohen JC, Hobbs HH. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology 2017;66:1111-24.
33. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46:352-6.
34. Abul-Husn NS, Cheng X, Li AH, et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med 2018;378:1096-106.
35. Day CP, James OFW. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998;114:842-5.
36. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55:1389-97.
37. Pal M, Febbraio MA, Lancaster GI. The roles of c-Jun NH2-terminal kinases (JNKs) in obesity and insulin resistance. J Physiol 2016;594:267-79.
38. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141-8.
39. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 2017;65:350-62.
40. Bril F, Barb D, Portillo-Sanchez P, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology 2017;65:1132-44.

41. Han J, Kaufman RJ. The role of ER stress in lipid metabolism and lipotoxicity. J Lipid Res 2016;57:1329-38.
42. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-69.
43. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 2012;287:40732-44.
44. Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg 2013;23:1815-25.
45. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-85.
46. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. Journal of hepatology 2003;39:239-44.
47. Huang JF, Hsieh MY, Dai CY, et al. The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. Gut 2007;56:736-7.
48. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-20.
49. European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of hepatology 2015;63:237-64.
50. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009;51:1061-7.
51. de Lédinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. Journal of hepatology 2014;60:1026-31.
52. Karcaaltincaba M, Akhan O. Imaging of hepatic steatosis and fatty sparing. Eur J Radiol 2007;61:33-43.
53. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.
54. Petta S, Maida M, Macaluso FS, et al. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology 2015;62:1101-10.
55. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.
56. Maersk M, Belza A, Stodkilde-Jorgensen H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr 2012;95:283-9.
57. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. Journal of hepatology 2007;47:711-7.
58. Estruch R, Ros E, Salas-Salvado J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018;378:e34.
59. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int 2017.

60. Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism 2017;68:119-32.
61. Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. Journal of hepatology 2017;66:142-52.
62. Lee Y, Doumouras AG, Yu J, et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:1040-60 e11.
63. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine 2010;362:1675-85.
64. Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016;150:1147-59 e5.
65. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet 2015;385:956-65.
66. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-90.
67. Friedman S, Sanyal A, Goodman Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemporary Clinical Trials 2016;47:356-65.
68. Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology 2018;67:549-59.
69. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. Journal of hepatology 2014;60:110-7.
70. Singal AK, Salameh H, Kuo YF, Wiesner RH. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation 2014;98:216-21.
71. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). Journal of hepatology 2012;57:675-88.
72. Singhal A, Wilson GC, Wima K, et al. Impact of recipient morbid obesity on outcomes after liver transplantation. Transpl Int 2015;28:148-55.
73. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008;8:667-72.
74. Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. Journal of hepatology 2019;71:313-22.
75. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010;16:431-9.
76. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
77. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.

78. Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology 2016;63:138-47.
79. Roulot D, Costes JL, Buyck JF, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011;60:977-84.
80. Serfaty L. Clinical Implications of Concomitant Alcohol Use, Obesity, and Viral Hepatitis. Gastroenterology;150:1718-22.
81. Marventano S, Salomone F, Godos J, et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr 2016.
82. Yesil A, Yilmaz Y. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:1038-44.
83. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 2009;16:85-91.
84. Khan N, Mukhtar H. Tea and Health: Studies in Humans. Curr Pharm Des 2013;19:6141-7.
85. Arnesen E, Huseby N-E, Brenn T, Try K. The Tromsø Heart Study: Distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scandinavian Journal of Clinical and Laboratory Investigation 1986;46:63-70.
86. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005;128:24-32.
87. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. AM J EPIDEMIOL 1992;136:1248-57.
88. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010;51:201-9.
89. Anty R, Marjoux S, Iannelli A, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. Journal of hepatology 2012;57:1090-6.
90. Bambha K, Wilson LA, Unalp A, et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 2014;34:1250-8.
91. Zelber-Sagi S, Salomone F, Webb M, et al. Coffee consumption and nonalcoholic fatty liver onset: A prospective study in the general population. Transl Res 2015;165:428-36.
92. Klatsky AL, Morton C, Udaltsova N, Friedman GD. COffee, cirrhosis, and transaminase enzymes. Archives of Internal Medicine 2006;166:1190-5.
93. Tanaka K, Tokunaga S, Kono S, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998;27:438-43.
94. Kono S, Shinchi K, Imanishi K, Todoroki I, Hatsuse K. Coffee and serum gamma-glutamyltransferase: a study of self-defense officials in Japan. Am J Epidemiol 1994;139:723-7.
95. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. Bmj 1995;310:693-6.
96. Sakata R, Nakamura T, Torimura T, Ueno T, Sata M. Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study. Int J Mol Med 2013;32:989-94.
97. Hofman A, Brusselle GG, Darwish Murad S, et al. The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol 2015;30:661-708.

98. Goldbohm RA, van den Brandt PA, Brants HA, et al. Validation of a dietary questionnaire used in a large-scale prospective cohort study on diet and cancer. Eur J Clin Nutr 1994;48:253-65.
99. Feunekes GI, Van Staveren WA, De Vries JH, Burema J, Hautvast JG. Relative and biomarker-based validity of a food-frequency questionnaire estimating intake of fats and cholesterol. Am J Clin Nutr 1993;58:489-96.
100. van Lee L, Geelen A, van Huysduynen EJ, de Vries JH, van't Veer P, Feskens EJ. The Dutch Healthy Diet index (DHD-index): an instrument to measure adherence to the Dutch Guidelines for a Healthy Diet. Nutr J 2012;11:49.
101. Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57:1182-91.
102. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-62.
103. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. Journal of hepatology 2008;48:835-47.
104. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708-15.
105. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
106. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
107. Willett WC, Reynolds RD, Cottrell-Hoehner S, Sampson L, Browne ML. Validation of a semi-quantitative food frequency questionnaire: comparison with a 1-year diet record. J Am Diet Assoc 1987;87:43-7.
108. Cassinotto C, Boursier J, de Ledinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology 2016;63:1817-27.
109. Goldbohm RA, van 't Veer P, van den Brandt PA, et al. Reproducibility of a food frequency questionnaire and stability of dietary habits determined from five annually repeated measurements. Eur J Clin Nutr 1995;49:420-9.
110. Liu F, Wang X, Wu G, et al. Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS One 2015;10:e0142457.
111. Triantos C MS, Smirnidis A. Is caffeine responsible for the hepatoprotective effect of coffee consumption in patients with chronic liver diseases? A multicentre study. AASLD abstract 2013;1.
112. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012;55:429-36.
113. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005;129:1928-36.
114. Honjo S, Kono S, Coleman MP, et al. Coffee consumption and serum aminotransferases in middle-aged Japanese men. Journal of Clinical Epidemiology 2001;54:823-9.
115. Carlsen MH, Halvorsen BL, Holte K, et al. The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr J 2010;9:3.

116. Shim SG, Jun DW, Kim EK, et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol 2013;28:1877-84.
117. Furtado KS, Prado MG, Aguiar ESMA, et al. Coffee and caffeine protect against liver injury induced by thioacetamide in male Wistar rats. Basic Clin Pharmacol Toxicol 2012;111:339-47.
118. Vitaglione P, Morisco F, Mazzone G, et al. Coffee Reduces Liver Damage in a Rat Model of Steatohepatitis: The Underlying Mechanisms and the Role of Polyphenols and Melanoidins. Hepatology 2010;52:1652-61.
119. Rodriguez de Sotillo DV, Hadley M, Sotillo JE. Insulin receptor exon 11+/– is expressed in Zucker (fa/fa) rats, and chlorogenic acid modifies their plasma insulin and liver protein and DNA. J Nutr Biochem 2006;17:63-71.
120. Xiao J, Ho CT, Liong EC, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr 2014;53:187-99.
121. Nakamuta M, Higashi N, Kohjima M, et al. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int J Mol Med 2005;16:677-81.
122. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-74.
123. Rustan AC, Halvorsen B, Ranheim T, Drevon CA. Cafestol (a coffee lipid) decreases uptake of low-density lipoprotein (LDL) in human skin fibroblasts and liver cells. ANN NEW YORK ACAD SCI1997:158-62.
124. Treur JL, Taylor AE, Ware JJ, et al. Associations between smoking and caffeine consumption in two European cohorts. Addiction 2016;111:1059-68.
125. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. Bmj 2017;359:j5024.
126. Arnesen E, Huseby NE, Brenn T, Try K. The Tromso Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest 1986;46:63-70.
127. Nakanishi N, Nakamura K, Nakajima K, Suzuki K, Tatara K. Coffee consumption and decreased serum γ-glutamyltransferase: A study of middle-aged Japanese men. Eur J Epidemiol 2000;16:419-23.
128. Xiao Q, Sinha R, Graubard BI, Freedman ND. Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999-2010. Hepatology 2014;60:2091-8.
129. Corrao G, Lepore AR, Torchio P, et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. EUR J EPIDEMIOL 1994;10:657-64.
130. Alferink LJM, Fittipaldi J, Kiefte-de Jong JC, et al. Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study. Journal of hepatology 2017;67:339-48.
131. Liu F, Wang X, Wu G, et al. Coffee consumption decreases risks for hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS ONE 2015;10.
132. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta-analysis: Coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther 2016;43:562-74.
133. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011;140:1961-9.

134. Carrieri MP, Protopopescu C, Marcellin F, et al. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. Journal of hepatology 2017;67:1157-67.
135. Cardin R, Piciocchi M, Martines D, Scribano L, Petracco M, Farinati F. Effects of coffee consumption in chronic hepatitis C: A randomized controlled trial. Dig Liver Dis 2013;45:499-504.
136. Shen H, Rodriguez AC, Shiani A, et al. Association between caffeine consumption and nonalcoholic fatty liver disease: A systemic review and meta-analysis. Ther Adv Gastroenterol 2016;9:113-20.
137. Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:e8-e12.
138. Veronese N, Notarnicola M, Cisternino AM, et al. Coffee Intake and Liver Steatosis: A Population Study in a Mediterranean Area. Nutrients 2018;10.
139. Bravi F, Tavani A, Bosetti C, Boffetta P, La Vecchia C. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: A systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017;26:368-77.
140. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-Analysis. BMJ Open 2017;7.
141. Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nutr 2011;51:363-73.
142. Sacchetti G, Di Mattia C, Pittia P, Mastrocola D. Effect of roasting degree, equivalent thermal effect and coffee type on the radical scavenging activity of coffee brews and their phenolic fraction. Journal of Food Engineering 2009;90:74-80.
143. Lang R, Yagar EF, Wahl A, et al. Quantitative studies on roast kinetics for bioactives in coffee. J Agric Food Chem 2013;61:12123-8.
144. Moroney KM, Lee WT, O'Brien SB, Suijver F, Marra J. Coffee extraction kinetics in a well mixed system. J Math Ind 2016;7:3.
145. Mojska H, Gielecinska I. Studies of acrylamide level in coffee and coffee substitutes: influence of raw material and manufacturing conditions. Rocz Panstw Zakl Hig 2013;64:173-81.
146. Duarte GS, Farah A. Effect of simultaneous consumption of milk and coffee on chlorogenic acids' bioavailability in humans. J Agric Food Chem 2011;59:7925-31.
147. Renouf M, Marmet C, Guy P, et al. Nondairy creamer, but not milk, delays the appearance of coffee phenolic acid equivalents in human plasma. J Nutr 2010;140:259-63.
148. Williamson G. The role of polyphenols in modern nutrition. Nutr Bull 2017;42:226-35.
149. Yagasaki K, Miura Y, Okauchi R, Furuse T. Inhibitory effects of chlorogenic acid and its related compounds on the invasion of hepatoma cells in culture. Cytotechnology 2000;33:229-35.
150. Gross G, Jaccaud E, Huggett AC. Analysis of the content of the diterpenes cafestol and kahweol in coffee brews. Food Chem Toxicol 1997;35:547-54.
151. Urgert R, Katan MB. The cholesterol-raising factor from coffee beans. Journal of the Royal Society of Medicine 1996;89:618-23.
152. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 2002;40:1155-63.
153. Moreira AS, Nunes FM, Domingues MR, Coimbra MA. Coffee melanoidins: structures, mechanisms of formation and potential health impacts. Food Funct 2012;3:903-15.
154. Cronstein BN. Caffeine, a drug for all seasons. Journal of hepatology 2010;53:207-8.

155. Dranoff JA. Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis. Gene Expr 2018;18:1-3.
156. Yang A, Palmer AA, de Wit H. Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl) 2010;211:245-57.
157. Farag NH, Vincent AS, McKey BS, Whitsett TL, Lovallo WR. Hemodynamic mechanisms underlying the incomplete tolerance to caffeine's pressor effects. Am J Cardiol 2005;95:1389-92.
158. Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment Pharmacol Ther 2007;26:1-8.
159. Hemmerle H, Burger HJ, Below P, et al. Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. J Med Chem 1997;40:137-45.
160. Rodriguez de Sotillo DV, Hadley M. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem 2002;13:717-26.
161. Ong KW, Hsu A, Tan BKH. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation. Biochemical Pharmacology 2013;85:1341-51.
162. Ma YJ, Gao MM, Liu DX. Chlorogenic Acid Improves High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice. Pharmaceutical Research 2015;32:1200-9.
163. Shokouh P, Jeppesen PB, Hermansen K, et al. A Combination of Coffee Compounds Shows Insulin-Sensitizing and Hepatoprotective Effects in a Rat Model of Diet-Induced Metabolic Syndrome. Nutrients 2017;10.
164. Murase T, Misawa K, Minegishi Y, et al. Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice. American Journal of Physiology-Endocrinology and Metabolism 2011;300:E122-E33.
165. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996;239:70-6.
166. Panchal SK, Poudyal H, Waanders J, Brown L. Coffee Extract Attenuates Changes in Cardiovascular and Hepatic Structure and Function without Decreasing Obesity in High-Carbohydrate, High-Fat Diet-Fed Male Rats. Journal of Nutrition 2012;142:690-7.
167. Salomone F, Li Volti G, Vitaglione P, et al. Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. Transl Res 2014;163:593-602.
168. Watanabe S, Takahashi T, Ogawa H, et al. Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice. Metab syndr relat disord 2017;15:170-7.
169. Takahashi S, Egashira K, Saito K, Jia H, Abe K, Kato H. Coffee intake down-regulates the hepatic gene expression of peroxisome proliferator-activated receptor gamma in C57BL/6J mice fed a high-fat diet. Journal of Functional Foods 2014;6:157-67.
170. Yun JW, Shin ES, Cho SY, et al. The effects of BADGE and caffeine on the time-course response of adiponectin and lipid oxidative enzymes in high fat diet-fed C57BL/6J mice: Correlation with reduced adiposity and steatosis. Experimental Animals 2008;57:461-9.
171. Sinha RA, Farah BL, Singh BK, et al. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology 2014;59:1366-80.
172. Helal MG, Ayoub SE, Elkashefand WF, Ibrahim TM. Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention. Hum Exp Toxicol 2017:960327117747026.
173. Sugiura C, Nishimatsu S, Moriyama T, Ozasa S, Kawada T, Sayama K. Catechins and Caffeine Inhibit Fat Accumulation in Mice through the Improvement of Hepatic Lipid Metabolism. J Obes 2012;2012:520510.

174. Zheng X, Dai W, Chen X, et al. Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae. J Biomed Sci 2015;22:105.
175. Reyes MT, Mourelle M, Hong E, Muriel P. Caffeic acid prevents liver damage and ameliorates liver fibrosis induced by CCl4 in the rat. Drug Development Research 1995;36:125-8.
176. Janbaz KH, Saeed SA, Gilani AH. Studies on the protective effects of caffeic acid and quercetin on chemical-induced hepatotoxicity in rodents. Phytomedicine 2004;11:424-30.
177. Shi HT, Dong L, Jiang J, et al. Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway. Toxicology 2013;303:107-14.
178. Pang C, Shi L, Sheng Y, et al. Caffeic acid attenuated acetaminophen-induced hepatotoxicity by inhibiting ERK1/2-mediated early growth response-1 transcriptional activation. Chem -Biol Interact 2016;260:186-95.
179. Pang C, Zheng Z, Shi L, et al. Caffeic acid prevents acetaminophen-induced liver injury by activating the Keap1-Nrf2 antioxidative defense system. Free Radic Biol Med 2016;91:236-46.
180. Ghahhari J, Vaezi G, Riazi G, Abbasi A, Modanloo M, Shokrzadeh M. The protective effect of chlorogenic acid on arsenic trioxide induced hepatotoxicity in mice. Bioscience Biotechnology Research Communications 2017;10:165-72.
181. Cavin C, Marin-Kuan M, Langouet S, et al. Induction of Nrf2-mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver. Food Chem Toxicol 2008;46:1239-48.
182. Ali N, Rashid S, Nafees S, et al. Protective effect of Chlorogenic acid against methotrexate induced oxidative stress, inflammation and apoptosis in rat liver: An experimental approach. Chemico-biological interactions 2017;272:80-91.
183. Lee KJ, Choi JH, Jeong HG. Hepatoprotective and antioxidant effects of the coffee diterpenes kahweol and cafestol on carbon tetrachloride-induced liver damage in mice. Food and Chemical Toxicology 2007;45:2118-25.
184. Poyrazoglu OK, Bahcecioglu IH, Ataseven H, et al. Effect of unfiltered coffee on carbon tetrachloride-induced liver injury in rats. Inflammation 2008;31:408-13.
185. Seo HY, Jung YA, Lee SH, et al. Kahweol decreases hepatic fibrosis by inhibiting the expression of connective tissue growth factor via the transforming growth factor-beta signaling pathway. Oncotarget 2017;8:87086-94.
186. He P, Noda Y, Sugiyama K. Suppression of lipopolysaccharide-induced liver injury by various types of tea and coffee in D-Galactosamine-sensitized rats. Bioscience Biotechnology and Biochemistry 2001;65:670-3.
187. Ozercan IH, Dagli AF, Ustundag B, et al. Does instant coffee prevent acute liver injury induced by carbon tetrachloride (CCl(4))? Hepatol res 2006;35:163-8.
188. Shi HY, Dong L, Zhang Y, Bai YH, Zhao JH, Zhang L. Protective effect of a coffee preparation (Nescafe pure (R)) against carbon tetrachloride-induced liver fibrosis in rats. Clinical Nutrition 2010;29:399-405.
189. Shin JW, Wang JH, Kang JK, Son CG. Experimental evidence for the protective effects of coffee against liver fibrosis in SD rats. Journal of the Science of Food and Agriculture 2010;90:450-5.
190. Abreu RV, Moraes-Santos T. The Protective Effect of Coffee against Paracetamol-Induced Hepatic Injury in Rats. Journal of Food Biochemistry 2011;35:1653-9.
191. Moreno MG, Chavez E, Aldaba-Muruato LR, et al. Coffee prevents CCl(4)-induced liver cirrhosis in the rat. Hepatol Int 2011;5:857-63.
192. Furtado KS, Prado MG, Silva M, et al. Coffee and Caffeine Protect against Liver Injury Induced by Thioacetamide in Male Wistar Rats. Basic & Clinical Pharmacology & Toxicology 2012;111:339-47.

193. Arauz J, Galicia-Moreno M, Cortes-Reynosa P, Salazar EP, Muriel P. Coffee attenuates fibrosis by decreasing the expression of TGF-beta and CTGF in a murine model of liver damage. Journal of Applied Toxicology 2013;33:970-9.
194. Arauz J, Zarco N, Hernandez-Aquino E, et al. Coffee consumption prevents fibrosis in a rat model that mimics secondary biliary cirrhosis in humans. Nutr Res 2017;40:65-74.
195. Sugiyama K, Noda Y, He P. Suppressive effect of caffeine on hepatitis and apoptosis induced by tumor necrosis factor-alpha, but not by the anti-Fas antibody, in mice. Bioscience, biotechnology, and biochemistry 2001;65:674-7.
196. Chan ESL, Montesinos MC, Fernandez P, et al. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol 2006;148:1144-55.
197. Hsu SJ, Lee FY, Wang SS, et al. Caffeine Ameliorates Hemodynamic Derangements and Portosystemic Collaterals in Cirrhotic Rats. Hepatology 2015;61:1672-84.
198. Klemmer I, Yagi S, Gressner OA. Oral application of 1,7-dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis. Hepatol res 2011;41:1094-109.
199. Gordillo-Bastidas D, Oceguera-Contreras E, Salazar-Montes A, Gonzalez-Cuevas J, Hernandez-Ortega LD, Armendariz-Borunda J. Nrf2 and Snail-1 in the prevention of experimental liver fibrosis by caffeine. World Journal of Gastroenterology 2013;19:9020-33.
200. Arauz J, Zarco N, Segovia J, Shibayama M, Tsutsumi V, Muriel P. Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-beta. European Journal of Gastroenterology & Hepatology 2014;26:164-73.
201. Wang Q, Dai XF, Yang WZ, et al. Caffeine protects against alcohol-induced liver fibrosis by dampening the cAMP/PKA/CREB pathway in rat hepatic stellate cells. International Immunopharmacology 2015;25:340-52.
202. Amer MG, Mazen NF, Mohamed AM. Caffeine intake decreases oxidative stress and inflammatory biomarkers in experimental liver diseases induced by thioacetamide: Biochemical and histological study. International Journal of Immunopathology and Pharmacology 2017;30:13-24.
203. Cachón AU, Quintal-Novelo C, Medina-Escobedo G, Castro-Aguilar G, Moo-Puc RE. Hepatoprotective Effect of Low Doses of Caffeine on CCl4-Induced Liver Damage in Rats. Journal of dietary supplements 2017;14:158-72.
204. Mohamed MK, Khalaf MM, Abo-Youssef AM, Abo-Saif AA. Caffeineas a promising antifbrotic agent against CCL4-Induced liver fibrosis. International Journal of Pharmacy and Pharmaceutical Sciences 2017;9:42-7.
205. Eraky SM, El-Mesery M, El-Karef A, Eissa LA, El-Gayar AM. Silymarin and caffeine combination ameliorates experimentally-induced hepatic fibrosis through down-regulation of LPAR1 expression. Biomedicine and Pharmacotherapy 2018;101:49-57.
206. Gressner OA, Lahme B, Siluschek M, Gressner AM. Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in liver parenchymal cells. Liver International 2009;29:886-97.
207. Stich HF, Rosin MP, Bryson L. Inhibition of mutagenicity of a model nitrosation reaction by naturally occurring phenolics, coffee and tea. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1982;95:119-28.
208. Mori H, Tanaka T, Shima H, Kuniyasu T, Takahashi M. Inhibitory effect of chlorogenic acid on methylazoxymethanol acetate-induced carcinogenesis in large intestine and liver of hamsters. Cancer letters 1986;30:49-54.
209. Yan Y, Liu N, Hou N, Dong L, Li J. Chlorogenic acid inhibits hepatocellular carcinoma in vitro and in vivo. J Nutr Biochem 2017;46:68-73.

210. Schilter B, Perrin I, Cavin C, Huggett AC. Placental glutathione S-transferase (GST-P) induction as a potential mechanism for the anti-carcinogenic effect of the coffee-specific components cafestol and kahweol. Carcinogenesis 1996;17:2377-84.
211. Cavin C, Holzhauser D, Constable A, Huggett AC, Schilter B. The coffee-specific diterpenes cafestol and kahweol protect against aflatoxin B1-induced genotoxicity through a dual mechanism. Carcinogenesis 1998;19:1369-75.
212. Huber WW, Prustomersky S, Delbanco E, et al. Enhancement of the chemoprotective enzymes glucuronosyl transferase and glutathione transferase in specific organs of the rat by the coffee components kahweol and cafestol. Archives of Toxicology 2002;76:209-17.
213. Huber WW, Teitel CH, Coles BF, et al. Potential chemoprotective effects of the coffee components kahweol and cafestol palmitates via modification of hepatic N-acetyltransferase and glutathione S-transferase activities. Environmental and Molecular Mutagenesis 2004;44:265-76.
214. Huber WW, Rossmanith W, Grusch M, et al. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food and Chemical Toxicology 2008;46:1230-8.
215. Sparnins VL, Venegas PL, Wattenberg LW. Glutathione S-transferase activity: enhancement by compounds inhibiting chemical carcinogenesis and by dietary constituents. J Natl Cancer Inst 1982;68:493-6.
216. Higgins LG, Cavin C, Itoh K, Yamamoto M, Hayes JD. Induction of cancer chemopreventive enzymes by coffee is mediated by transcription factor Nrf2. Evidence that the coffee-specific diterpenes cafestol and kahweol confer protection against acrolein. Toxicology and applied pharmacology 2008;226:328-37.
217. Morii H, Kuboyama A, Nakashima T, et al. Effects of Instant Coffee Consumption on Oxidative DNA Damage, DNA Repair, and Redox System in Mouse Liver. Journal of Food Science 2009;74:H155-H61.
218. Kalthoff S, Ehmer U, Freiberg N, Manns MP, Strassburg CP. Coffee induces expression of glucuronosyl transferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010;139:1699-710.e2.
219. Pietrocola F, Malik SA, Marino G, et al. Coffee induces autophagy in vivo. Cell cycle (Georgetown, Tex) 2014;13:1987-94.
220. Hasegawa R, Ogiso T, Imaida K, Shirai T, Ito N. Analysis of the potential carcinogenicity of coffee and its related compounds in a medium-term liver bioassay of rats. Food and Chemical Toxicology 1995;33:15-20.
221. Miura Y, Ono K, Okauchi R, Yagasaki K. Inhibitory effect of coffee on hepatoma proliferation and invasion in culture and on tumor growth, metastasis and abnormal lipoprotein profiles in hepatoma-bearing rats. Journal of nutritional science and vitaminology 2004;50:38-44.
222. Silva-Oliveira EM, Fernandes PA, Moraes-Santos T. Effect of coffee on chemical hepatocarcinogenesis in rats. Nutrition and Cancer 2010;62:336-42.
223. Ferk F, Huber WW, Grasl-Kraupp B, et al. Protective effects of coffee against induction of DNA damage and pre-neoplastic foci by aflatoxin B-1. Molecular Nutrition & Food Research 2014;58:229-38.
224. Furtado KS, Polletini J, Dias MC, Rodrigues MAM, Barbisan LF. Prevention of rat liver fibrosis and carcinogenesis by coffee and caffeine. Food and Chemical Toxicology 2014;64:20-6.
225. Katayama M, Donai K, Sakakibara H, et al. Coffee consumption delays the hepatitis and suppresses the inflammation related gene expression in the Long-Evans Cinnamon rat. Clinical Nutrition 2014;33:302-10.

226. Fujise Y, Okano JI, Nagahara T, Abe R, Imamoto RYU, Murawaki Y. Preventive effect of caffeine and curcumin on hepatocarcinogenesis in diethylnitrosamine-induced rats. International Journal of Oncology 2012;40:1779-88.
227. Hosaka S, Kawa S, Aoki Y, et al. Hepatocarcinogenesis inhibition by caffeine in ACI rats treated with 2-acetylaminofluorene. Food and Chemical Toxicology 2001;39:557-61.
228. Boekschoten MV, Hofman MK, Buytenhek R, Schouten EG, Princen HMG, Katan MB. Coffee oil consumption increases plasma levels of 7α-hydroxy-4- cholesten-3-one in humans. J Nutr 2005;135:785-9.
229. Boekschoten MV, Schouten EG, Katan MB. Coffee bean extracts rich and poor in kahweol both give rise to elevation of liver enzymes in healthy volunteers. Nutr J 2004;3.
230. Bichler J, Cavin C, Simic T, et al. Coffee consumption protects human lymphocytes against oxidative and 3-amino-1-methyl-5H-pyrido [4,3-b]indole acetate (Trp-P-2) induced DNA-damage: Results of an experimental study with human volunteers. Food and Chemical Toxicology 2007;45:1428-36.
231. Shaposhnikov S, Hatzold T, Yamani NE, et al. Coffee and oxidative stress: a human intervention study. Eur J Nutr 2016:1-12.
232. Shahmohammadi HA, Hosseini SA, Hajiani E, Malehi AS, Alipour M. Effects of green coffee bean extract supplementation on patients with non-alcoholic fatty liver disease: A randomized clinical trial. Hepat Mon 2017;17.
233. Jaquet M, Rochat I, Moulin J, Cavin C, Bibiloni R. Impact of coffee consumption on the gut microbiota: a human volunteer study. Int J Food Microbiol 2009;130:117-21.
234. Nakayama T, Oishi K. Influence of coffee (Coffea arabica) and galacto-oligosaccharide consumption on intestinal microbiota and the host responses. FEMS Microbiol Lett 2013;343:161-8.
235. Cowan TE, Palmnas MS, Yang J, et al. Chronic coffee consumption in the diet-induced obese rat: impact on gut microbiota and serum metabolomics. J Nutr Biochem 2014;25:489-95.
236. Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. Journal of hepatology 2018;68:230-7.
237. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
238. Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2016;65:1359-68.
239. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
240. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015;149:367-78 e5; quiz e14-5.
241. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9.
242. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91:319-27.
243. Fonseca J, Nunes G, Fonseca C, Canhoto M, Barata AT, Santos CA. Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". Journal of hepatology 2017;66:465-6.
244. Ha V, Cozma AI, Choo VLW, Mejia SB, de Souza RJ, Sievenpiper JL. Do Fructose-Containing Sugars Lead to Adverse Health Consequences? Results of Recent Systematic Reviews and Meta-analyses. Advances in Nutrition: An International Review Journal 2015;6:504S-11S.

245. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006;25:816-23.
246. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 2009;44:471-7.
247. Rietman A, Sluik D, Feskens EJM, Kok FJ, Mensink M. Associations between dietary factors and markers of NAFLD in a general Dutch adult population. Eur J Clin Nutr 2018;72:117-23.
248. Ikram MA, Brusselle GGO, Murad SD, et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol 2017;32:807-50.
249. Feunekes IJ, Van Staveren WA, Graveland F, De Vos J, Burema J. Reproducibility of a semi-quantitative food frequency questionnaire to assess the intake of fats and cholesterol in The Netherlands. Int J Food Sci Nutr 1995;46:117-23.
250. Donders-Engelen MR, Heijden Lvd, Hulshof KFAM, Vakgroep Humane Voeding LW, Zeist TNOV. Maten, gewichten en codenummers 1997. Wageningen: Vakgroep Humane Voeding; 1997.
251. Freedman LS, Schatzkin A, Midthune D, Kipnis V. Dealing with dietary measurement error in nutritional cohort studies. J Natl Cancer Inst 2011;103:1086-92.
252. Fallaize R, Livingstone KM, Celis-Morales C, et al. Association between Diet-Quality Scores, Adiposity, Total Cholesterol and Markers of Nutritional Status in European Adults: Findings from the Food4Me Study. Nutrients 2018;10.
253. Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Bmj 2009;338.
254. Rubin DB. Multiple imputation for nonresponse in surveys. Wiley London 1987.
255. Hu FB, Stampfer MJ, Rimm E, et al. Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol 1999;149:531-40.
256. Šidák Z. Rectangular Confidence Regions for the Means of Multivariate Normal Distributions. Journal of the American Statistical Association 1967;62:626-33.
257. Galwey NW. A new measure of the effective number of tests, a practical tool for comparing families of non-independent significance tests. Genet Epidemiol 2009;33:559-68.
258. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. Journal of hepatology 2017.
259. Chan R, Wong VW, Chu WC, et al. Higher estimated net endogenous Acid production may be associated with increased prevalence of nonalcoholic Fatty liver disease in chinese adults in Hong Kong. PLoS One 2015;10:e0122406.
260. Etemadi A, Sinha R, Ward MH, et al. Mortality from different causes associated with meat, heme iron, nitrates, and nitrites in the NIH-AARP Diet and Health Study: population based cohort study. Bmj 2017;357:j1957.
261. Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss Isakov N, et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. Journal of hepatology 2018.
262. Markova M, Pivovarova O, Hornemann S, et al. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. Gastroenterology 2017;152:571-85 e8.
263. Haghighatdoost F, Salehi-Abargouei A, Surkan PJ, Azadbakht L. The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. J Res Med Sci 2016;21:53.

264. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009;136:1552-60.
265. Johnston RD, Stephenson MC, Crossland H, et al. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology 2013;145:1016-25 e2.
266. Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol 2016;9:392-407.
267. Mosca A, Nobili V, De Vito R, et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. Journal of hepatology 2017;66:1031-6.
268. Bozzetto L, Prinster A, Annuzzi G, et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 2012;35:1429-35.
269. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 2014;160:398-406.
270. de Souza RJ, Mente A, Maroleanu A, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. Bmj 2015;351:h3978.
271. Romeu M, Aranda N, Giralt M, Ribot B, Nogues MR, Arija V. Diet, iron biomarkers and oxidative stress in a representative sample of Mediterranean population. Nutr J 2013;12:102.
272. Pereira EC, Ferderbar S, Bertolami MC, et al. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem 2008;41:1454-60.
273. Freedman ND, Cross AJ, McGlynn KA, et al. Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst 2010;102:1354-65.
274. Adeva MM, Souto G. Diet-induced metabolic acidosis. Clin Nutr 2011;30:416-21.
275. Krupp D, Johner SA, Kalhoff H, Buyken AE, Remer T. Long-term dietary potential renal acid load during adolescence is prospectively associated with indices of nonalcoholic fatty liver disease in young women. J Nutr 2012;142:313-9.
276. Rebolledo OR, Hernandez RE, Zanetta AC, Gagliardino JJ. Insulin secretion during acid-base alterations. Am J Physiol 1978;234:E426-9.
277. Schoufour JD, de Jonge EAL, Kiefte-de Jong JC, et al. Socio-economic indicators and diet quality in an older population. Maturitas;107:71-7.
278. Gemming L, Jiang Y, Swinburn B, Utter J, Mhurchu CN. Under-reporting remains a key limitation of self-reported dietary intake: an analysis of the 2008/09 New Zealand Adult Nutrition Survey. Eur J Clin Nutr 2014;68:259-64.
279. Rothman KJG, Sander; Lash Timothy. Modern Epidemiology. Philedelphia: Wolters KLuewer health/ Lippincott Williams & Wilkins, c2008 1951;3rd ed.
280. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 2018;69:718-35.
281. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine 2018;24:908-22.
282. Hagstrom H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017;67:1265-73.

283. Blond E, Disse E, Cuerq C, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia 2017;60:1218-22.
284. Ferolla SM, Silva LC, Ferrari Mde L, et al. Dietary approach in the treatment of nonalcoholic fatty liver disease. World J Hepatol 2015;7:2522-34.
285. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int 2017;37:936-49.
286. Oddy WH, Herbison CE, Jacoby P, et al. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol 2013;108:778-85.
287. Alferink LJM, Kiefte-de Jong JC, Erler NS, et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 2018.
288. Kiefte-de Jong JC, Li Y, Chen M, et al. Diet-dependent acid load and type 2 diabetes: pooled results from three prospective cohort studies. Diabetologia 2017;60:270-9.
289. Han E, Kim G, Hong N, et al. Association between dietary acid load and the risk of cardiovascular disease: nationwide surveys (KNHANES 2008-2011). Cardiovasc Diabetol 2016;15:122.
290. Remer T. Influence of diet on acid-base balance. Semin Dial 2000;13:221-6.
291. Frassetto LA, Todd KM, Morris RC, Jr., Sebastian A. Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. Am J Clin Nutr 1998;68:576-83.
292. Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Low urine pH is a risk for non-alcoholic fatty liver disease: A population-based longitudinal study. Clin Res Hepatol Gastroenterol 2018.
293. Miyake T, Yoshida S, Yamamoto S, et al. Low Urine pH is Associated with Non-alcoholic Fatty Liver Disease: A Community-based Cross-sectional Study. Intern Med 2018.
294. Alferink LJM, Kiefte-de Jong JC, Erler NS, et al. Diet-dependent acid load - the missing link between an animal protein-rich diet and non-alcoholic fatty liver disease? Deposited 13 March 2019. https://repubeurnl/pub/115477.
295. Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc 1995;95:791-7.
296. Zwart SR, Hargens AR, Smith SM. The ratio of animal protein intake to potassium intake is a predictor of bone resorption in space flight analogues and in ambulatory subjects. Am J Clin Nutr 2004;80:1058-65.
297. Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988;66:140-6.
298. (Gezondheidsraad) DHC. Dutch dietary guidelines 2015 (richtlijnen goede voeding 2015). The Hague 2015;2015/24.
299. Stel VS, Smit JH, Pluijm SM, Visser M, Deeg DJ, Lips P. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. J Clin Epidemiol 2004;57:252-8.
300. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-9.
301. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Bmj 2009;338:b2393.
302. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 1997;65:1220S-8S; discussion 9S-31S.

303. Carnauba RA, Baptistella AB, Paschoal V, Hubscher GH. Diet-Induced Low-Grade Metabolic Acidosis and Clinical Outcomes: A Review. Nutrients 2017;9.
304. Akter S, Kurotani K, Kashino I, et al. High Dietary Acid Load Score Is Associated with Increased Risk of Type 2 Diabetes in Japanese Men: The Japan Public Health Center-based Prospective Study. J Nutr 2016;146:1076-83.
305. Kumar R, Mohan S. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. J Clin Transl Hepatol 2017;5:216-23.
306. McCarty MF. Acid-base balance may influence risk for insulin resistance syndrome by modulating cortisol output. Med Hypotheses 2005;64:380-4.
307. Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018;68:361-71.
308. Xu H, Akesson A, Orsini N, Hakansson N, Wolk A, Carrero JJ. Modest U-Shaped Association between Dietary Acid Load and Risk of All-Cause and Cardiovascular Mortality in Adults. J Nutr 2016;146:1580-5.
309. Engberink MF, Bakker SJ, Brink EJ, et al. Dietary acid load and risk of hypertension: the Rotterdam Study. Am J Clin Nutr 2012;95:1438-44.
310. Xu H, Jia T, Huang X, et al. Dietary acid load, insulin sensitivity and risk of type 2 diabetes in community-dwelling older men. Diabetologia 2014;57:1561-8.
311. Scialla JJ. The balance of the evidence on acid-base homeostasis and progression of chronic kidney disease. Kidney Int 2015;88:9-11.
312. Wesson DE, Simoni J, Broglio K, Sheather S. Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol 2011;300:F830-7.
313. Patience JF. A review of the role of acid-base balance in amino acid nutrition. J Anim Sci 1990;68:398-408.
314. Pizzorno J, Frassetto LA, Katzinger J. Diet-induced acidosis: is it real and clinically relevant? Br J Nutr 2010;103:1185-94.
315. Esche J, Shi L, Sanchez-Guijo A, Hartmann MF, Wudy SA, Remer T. Higher diet-dependent renal acid load associates with higher glucocorticoid secretion and potentially bioactive free glucocorticoids in healthy children. Kidney Int 2016;90:325-33.
316. Ordonez FA, Santos F, Martinez V, et al. Resistance to growth hormone and insulin-like growth factor-I in acidotic rats. Pediatr Nephrol 2000;14:720-5.
317. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem 2009;284:19937-44.
318. Wang PY, Fang JC, Gao ZH, Zhang C, Xie SY. Higher intake of fruits, vegetables or their fiber reduces the risk of type 2 diabetes: A meta-analysis. J Diabetes Investig 2016;7:56-69.
319. Jung Y-S. Metabolism of Sulfur-Containing Amino Acids in the Liver: A Link between Hepatic Injury and Recovery. Biological and Pharmaceutical Bulletin 2015;38:971-4.
320. Diaz-Rua R, Keijer J, Palou A, van Schothorst EM, Oliver P. Long-term intake of a high-protein diet increases liver triacylglycerol deposition pathways and hepatic signs of injury in rats. J Nutr Biochem 2017;46:39-48.
321. Schoufour JD, de Jonge EAL, Kiefte-de Jong JC, et al. Socio-economic indicators and diet quality in an older population. Maturitas 2018;107:71-7.
322. Raphael KL, Carroll DJ, Murray J, Greene T, Beddhu S. Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease. J Am Soc Nephrol 2017;28:2483-90.

323. Buuren van S, Groothuis-Oudhoorn K. mice: Multivariate Imputation by Chained Equations in R. Journal of Statistical Software, Articles 2011;45:1-67.
324. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. Journal of hepatology 2018;69:718-35.
325. Kim D, Li AA, Gadiparthi C, et al. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology 2018;155:1154-63.e3.
326. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Journal of hepatology 2018;69:896-904.
327. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
328. Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology 2018;67:1726-36.
329. Wong VW, Wong GL, Chan RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol 2018;69:1349-56.
330. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013;59:138-43.
331. Properzi C, O'Sullivan TA, Sherriff JL, et al. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology 2018;68:1741-54.
332. Khalatbari-Soltani S, Imamura F, Brage S, et al. The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study. BMC Medicine 2019;17:19.
333. Hu FB. Dietary pattern analysis: a new direction in nutritional epidemiology. Curr Opin Lipidol 2002;13:3-9.
334. Cespedes EM, Hu FB. Dietary patterns: from nutritional epidemiologic analysis to national guidelines. The American Journal of Clinical Nutrition 2015;101:899-900.
335. Ma J, Hennein R, Liu C, et al. Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. Gastroenterology 2018;155:107-17.
336. Koch M, Borggrefe J, Barbaresko J, et al. Dietary patterns associated with magnetic resonance imaging-determined liver fat content in a general population study. Am J Clin Nutr 2014;99:369-77.
337. Kalafati I-P, Borsa D, Dimitriou M, Revenas K, Kokkinos A, Dedoussis GV. Dietary patterns and non-alcoholic fatty liver disease in a Greek case–control study. Nutrition 2019;61:105-10.
338. Boursier J, Zarski J-P, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57:1182-91.
339. Kröger J, Ferrari P, Jenab M, et al. Specific food group combinations explaining the variation in intakes of nutrients and other important food components in the European Prospective Investigation into Cancer and Nutrition: an application of the reduced rank regression method. European Journal Of Clinical Nutrition 2009;63:S263.
340. Trichopoulou A, Lagiou P. Healthy traditional Mediterranean diet: an expression of culture, history, and lifestyle. Nutr Rev 1997;55:383-9.
341. Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. Bmj 2010;340:c1240.

342. WHO. https://www.who.int/news-room/fact-sheets/detail/healthy-diet. 2018.
343. Revelle W. Psych: Procedures for Psychological, Psychometric, and Personality Research. 2018.
344. Alferink LJ, Kiefte-de Jong JC, Erler NS, et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 2018.
345. Northstone K, Ness AR, Emmett PM, Rogers IS. Adjusting for energy intake in dietary pattern investigations using principal components analysis. Eur J Clin Nutr 2008;62:931-8.
346. Erler NS, Rizopoulos D, Lesaffre EMEH. JointAI: Joint Analysis and Imputation of Incomplete Data in R2019.
347. Erler NS, Rizopoulos D, Jaddoe VW, Franco OH, Lesaffre EM. Bayesian imputation of time-varying covariates in linear mixed models. Stat Methods Med Res 2019;28:555-68.
348. Erler NS, Rizopoulos D, Rosmalen J, Jaddoe VW, Franco OH, Lesaffre EM. Dealing with missing covariates in epidemiologic studies: a comparison between multiple imputation and a full Bayesian approach. Stat Med 2016;35:2955-74.
349. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet 2019;393:434-45.
350. De Filippis F, Pellegrini N, Vannini L, et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut 2016;65:1812-21.
351. Carvalhana S, Machado MV, Cortez-Pinto H. Improving dietary patterns in patients with non-alcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012;15:468-73.
352. Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss Isakov N, et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol 2018;68:1239-46.
353. Alferink LJM, Kiefte-de Jong JC, Erler NS, et al. Diet-dependent acid load - the missing link between an animal protein-rich diet and non-alcoholic fatty liver disease? J Clin Endocrinol Metab 2019.
354. Martinez R, Lopez-Jurado M, Wanden-Berghe C, Sanz-Valero J, Porres JM, Kapravelou G. Beneficial effects of legumes on parameters of the metabolic syndrome: a systematic review of trials in animal models. Br J Nutr 2016;116:402-24.
355. Romeu M, Aranda N, Giralt M, Ribot B, Nogues MR, Arija V. Diet, iron biomarkers and oxidative stress in a representative sample of Mediterranean population. Nutrition Journal 2013;12:102.
356. Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010;341:c5702.
357. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Jama 2007;297:842-57.
358. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in non-alcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54 e1-9; quiz e39-40.
359. Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol 2018;10:530-42.
360. Wu SD, Liu LL, Cheng JL, et al. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. Clin Exp Med 2018;18:433-43.
361. Hu FB, Rimm E, Smith-Warner SA, et al. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am J Clin Nutr 1999;69:243-9.

362. Trajanoska K, Schoufour JD, Darweesh SK, et al. Sarcopenia and Its Clinical Correlates in the General Population: The Rotterdam Study. Journal of Bone and Mineral Research 2018;33:1209-18.
363. Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019;16:517-30.
364. Lüdtke O, A. R, West SG. Analysis of Interactions and Nonlinear Effects with Missing Data: A Factored Regression Modeling Approach Using Maximum Likelihood Estimation. Multivariate Behavioral Research 2019:1-21.
365. Bartlett JW, Seaman SR, White IR, Carpenter JR, Alzheimer's Disease Neuroimaging I. Multiple imputation of covariates by fully conditional specification: Accommodating the substantive model. Stat Methods Med Res 2015;24:462-87.
366. Prentice AM, Jebb SA. Beyond body mass index. Obes Rev 2001;2:141-7.
367. Pang Q, Zhang JY, Song SD, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol 2015;21:1650-62.
368. Ko YH, Wong TC, Hsu YY, Kuo KL, Yang SH. The Correlation Between Body Fat, Visceral Fat, and Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2017;15:304-11.
369. Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol 2018;24:12-7.
370. Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. Journal of hepatology 2017;66:123-31.
371. Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;45:510-8.
372. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-42.
373. Lee DH, Keum N, Hu FB, et al. Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study. Bmj 2018;362.
374. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412-23.
375. Verlinden VJ, van der Geest JN, Hoogendam YY, Hofman A, Breteler MM, Ikram MA. Gait patterns in a community-dwelling population aged 50 years and older. Gait Posture 2013;37:500-5.
376. Trajanoska K, Schoufour JD, Darweesh SK, et al. Sarcopenia and Its Clinical Correlates in the General Population: The Rotterdam Study. J Bone Miner Res 2018.
377. Lafortuna CL, Maffiuletti NA, Agosti F, Sartorio A. Gender variations of body composition, muscle strength and power output in morbid obesity. Int J Obes (Lond) 2005;29:833-41.
378. Sakamoto Y, Ishiguro M, Kitagawa G. Akaike information criterion statistics. Tokyo; Dordrecht; Boston; Hingham, MA: KTK Scientific Publishers; D. Reidel; Sold and distributed in the U.S.A. and Canada by Kluwer Academic Publishers; 1986.
379. Willett W. Nutritional epidemiology. Oxford; New York: Oxford University Press; 2013.
380. Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014;59:1772-8.
381. Lee YH, Jung KS, Kim SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). Journal of hepatology 2015;63:486-93.

382. Kim HY, Kim CW, Park CH, et al. Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey. Hepatobiliary Pancreat Dis Int 2016;15:39-47.
383. Moon JS, Yoon JS, Won KC, Lee HW. The role of skeletal muscle in development of nonalcoholic Fatty liver disease. Diabetes Metab J 2013;37:278-85.
384. Kim G, Lee S-E, Lee Y-B, et al. Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study. Hepatology 2018;68:1755-68.
385. Issa D, Alkhouri N, Tsien C, et al. Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology 2014;60:428-9.
386. Zhai Y, Xiao Q, Miao J. The Relationship between NAFLD and Sarcopenia in Elderly Patients. Can J Gastroenterol Hepatol 2018;2018:5016091.
387. Meng G, Wu H, Fang L, et al. Relationship between grip strength and newly diagnosed nonalcoholic fatty liver disease in a large-scale adult population. Sci Rep 2016;6:33255.
388. Sakuma K, Yamaguchi A. Sarcopenia and Age-Related Endocrine Function. International Journal of Endocrinology 2012;2012:10.
389. Maggio M, Lauretani F, Ceda GP. Sex hormones and sarcopenia in older persons. Current Opinion in Clinical Nutrition & Metabolic Care 2013;16:3-13.
390. Walsh K. Adipokines, myokines and cardiovascular disease. Circ J 2009;73:13-8.
391. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:273-80.
392. Visser M, Kritchevsky SB, Goodpaster BH, et al. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc 2002;50:897-904.
393. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011;60:1278-83.
394. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011;30:377-99.
395. Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond) 2010;34:791-9.
396. Andreasson A, Carlsson AC, Onnerhag K, Hagstrom H. Waist/Hip Ratio Better Predicts Development of Severe Liver Disease Within 20 Years Than Body Mass Index: A Population-based Cohort Study. Clin Gastroenterol Hepatol 2017;15:1294-301 e2.
397. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.
398. Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol 2013;11:1201-4.
399. Pais R, Barritt AS, Calmus Y, et al. NAFLD and liver transplantation: Current burden and expected challenges. Journal of Hepatology 2016;65:1245-57.
400. Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. Bmj 2010;340.

401. Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clinical Gastroenterology and Hepatology 2019;17:296-306.
402. Cani PD. Human gut microbiome: hopes, threats and promises. Gut 2018.
403. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. New England Journal of Medicine 2016;375:2369-79.
404. Patterson E, Ryan PM, Cryan JF, et al. Gut microbiota, obesity and diabetes. Postgraduate Medical Journal 2016;92:286-300.
405. Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013;62:1787-94.
406. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011;140:976-86.
407. Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11:868-75 e1-3.
408. Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013;58:120-7.
409. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9.
410. Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015;5:8096.
411. Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 2015;91:1-9.
412. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-75.
413. Shen F, Zheng R-D, Sun X-Q, Ding W-J, Wang X-Y, Fan J-G. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary & Pancreatic Diseases International 2017;16:375-81.
414. Del Chierico F, Nobili V, Vernocchi P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 2017;65:451-64.
415. Da Silva HE, Teterina A, Comelli EM, et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep 2018;8:1466.
416. Duarte SMB, Stefano JT, Miele L, et al. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. Nutr Metab Cardiovasc Dis 2018;28:369-84.
417. Hoyles L, Fernandez-Real JM, Federici M, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 2018;24:1070-80.
418. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016;352:565-9.
419. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. Journal of Hepatology 2009;51:1061-7.

420. Radjabzadeh D, Boer CG, Beth SA, et al. Diversity, compositional and functional differences between gut microbiota of children and adults. Scientific Reports 2020;10:1040.
421. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007;73:5261-7.
422. Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 2013;41:D590-6.
423. Bokulich NA, Subramanian S, Faith JJ, et al. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. Nat Methods 2013;10:57-9.
424. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013;31:814-21.
425. Soininen P, Kangas AJ, Wurtz P, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009;134:1781-5.
426. Oksanen J, Blanchet FG, Friendly M, et al. vegan: Community Ecology Package. R package version 2.5-6. 2019.
427. Tibshirani R. Regression Shrinkage and Selection Via the Lasso. J R Stat Soc Ser B 1994:267–88
428. Lin W, Shi P, Feng R, Li H. Variable selection in regression with compositional covariates. Biometrika 2014;101:785-97.
429. Altenbuchinger M, Rehberg T, Zacharias HU, et al. Reference point insensitive molecular data analysis. Bioinformatics 2016;33:219-26.
430. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 1995;57:289-300.
431. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.
432. Murphy EF, Cotter PD, Healy S, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010;59:1635-42.
433. Wang B, Jiang X, Cao M, et al. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep 2016;6:32002.
434. Loomba R, Seguritan V, Li W, et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab 2017;25:1054-62 e5.
435. Shaw KA, Bertha M, Hofmekler T, et al. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome medicine 2016;8:75.
436. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013;500:541-6.
437. Domingo MC, Huletsky A, Boissinot M, Bernard KA, Picard FJ, Bergeron MG. Ruminococcus gauvreauii sp. nov., a glycopeptide-resistant species isolated from a human faecal specimen. International journal of systematic and evolutionary microbiology 2008;58:1393-7.
438. Jie Z, Xia H, Zhong S-L, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications 2017;8:845.
439. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011;60:631-7.
440. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559-63.

441. Kim CW, Addy C, Kusunoki J, et al. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab 2017;26:394-406.e6.
442. Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 2018;67:1881-91.
443. Kaikkonen JE, Wurtz P, Suomela E, et al. Metabolic profiling of fatty liver in young and middle-aged adults: Cross-sectional and prospective analyses of the Young Finns Study. Hepatology 2017;65:491-500.
444. Krumsiek J, Mittelstrass K, Do KT, et al. Gender-specific pathway differences in the human serum metabolome. Metabolomics 2015;11:1815-33.
445. Wurtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 2015;131:774-85.
446. Gruppen EG, Connelly MA, Sluiter WJ, Bakker SJL, Dullaart RPF. Higher plasma GlycA, a novel pro-inflammatory glycoprotein biomarker, is associated with reduced life expectancy: The PREVEND study. Clinica Chimica Acta 2019;488:7-12.
447. Hall AB, Tolonen AC, Xavier RJ. Human genetic variation and the gut microbiome in disease. Nature Reviews Genetics 2017;18:690-9.
448. Oksanen J, Blanchet FG, Friendly M, et al. Vegan: Community Ecology Package. 2018.
449. Altenbuchinger M, Rehberg T, Zacharias HU, et al. Reference point insensitive molecular data analysis. Bioinformatics 2017;33:219-26.
450. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biology 2011;12:R60.
451. Philips CA AP. Herbal tea consumption and the liver - all is not what is seems! Journal of hepatology 2017.
452. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. Journal of hepatology 2005;43:901-10.
453. Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y. Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. Int J Mol Sci 2016;17:465.
454. Navarro VJ, Bonkovsky HL, Hwang SI, Vega M, Barnhart H, Serrano J. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci 2013;58:2682-90.
455. Boehm K, Borrelli F, Ernst E, et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2009:CD005004.
456. Huang H, Y. H. Association between beverage consumption and liver fibrosis. Journal of hepatology.
457. Willet WC. Nutritional epidemiology. New York: Oxford University Press 2012.
458. Tang GY, Mann JP. Animal protein intake and hepatic steatosis in the elderly. Gut 2018.
459. Chiu S, Sievenpiper JL, de Souza RJ, et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 2014;68:416-23.
460. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166:1190-5.
461. Zelber-Sagi S, Salomone F, Webb M, et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res 2015;165:428-36.
462. Carrieri MP, Protopopescu C, Marcellin F, et al. The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. Journal of hepatology 2018;68:845-7.
463. Abby Philips C, Augustine P. Herbal tea consumption and the liver - All is not what it seems! Journal of hepatology 2018;68:612-3.

464. Huang H, Huang Y. Association between beverage consumption and liver fibrosis. Journal of hepatology 2018;68:1095-6.
465. NIH. LiverTox. Consulted on the 20th of December 2019.
466. Promrat K, Longato L, Wands JR, de la Monte SM. Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatology Research 2011;41:754-62.
467. Fonseca J, Nunes G, Fonseca C, Canhoto M, Barata AT, Santos CA. Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". Journal of hepatology 2017;66:465-6.
468. Ha V, Cozma AI, Choo VLW, Mejia SB, de Souza RJ, Sievenpiper JL. Do Fructose-Containing Sugars Lead to Adverse Health Consequences? Results of Recent Systematic Reviews and Meta-analyses. Adv Nutr 2015;6:504S-11S.
469. Tang GY, Mann JP. Animal protein intake and hepatic steatosis in the elderly. Gut 2019;68:2256-7.
470. Raphael KL, Carroll DJ, Murray J, Greene T, Beddhu S. Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease. Journal of the American Society of Nephrology 2017;28:2483-90.
471. Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 2019;17:296-306.
472. Response Rates NHANES. Consulted on 20th of December 2019.
473. Nohr EA, Frydenberg M, Henriksen TB, Olsen J. Does low participation in cohort studies induce bias? Epidemiology 2006;17:413-8.
474. Pizzi C, De Stavola B, Merletti F, et al. Sample selection and validity of exposure-disease association estimates in cohort studies. J Epidemiol Community Health 2011;65:407-11.
475. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002;359:248-52.
476. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med 1965;58:295-300.
477. VanderWeele TJ. Principles of confounder selection. European Journal of Epidemiology 2019;34:211-9.
478. Johnson AJ, Vangay P, Al-Ghalith GA, et al. Daily Sampling Reveals Personalized Diet-Microbiome Associations in Humans. Cell Host Microbe 2019;25:789-802 e5.
479. Vuik FER, Dicksved J, Lam SY, et al. Composition of the mucosa-associated microbiota along the entire gastrointestinal tract of human individuals. United European Gastroenterology Journal 2019;7:897-907.
480. Gorzelak MA, Gill SK, Tasnim N, Ahmadi-Vand Z, Jay M, Gibson DL. Methods for Improving Human Gut Microbiome Data by Reducing Variability through Sample Processing and Storage of Stool. PLoS One 2015;10:e0134802.
481. Lauber CL, Zhou N, Gordon JI, Knight R, Fierer N. Effect of storage conditions on the assessment of bacterial community structure in soil and human-associated samples. FEMS microbiology letters 2010;307:80-6.
482. Gibbons SM, Duvallet C, Alm EJ. Correcting for batch effects in case-control microbiome studies. PLoS Comput Biol 2018;14:e1006102.
483. Ginès P, Graupera I, Lammert F, et al. Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology & Hepatology 2016;1:256-60.
484. Hastings MH, Maywood ES, Brancaccio M. Generation of circadian rhythms in the suprachiasmatic nucleus. Nature Reviews Neuroscience 2018;19:453-69.

485. Levi F. Circadian chronotherapy for human cancers. Lancet Oncol 2001;2:307-15.
486. Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. Cell Metab 2018;27:1212-21 e3.
487. Waldman HS, Renteria LI, McAllister MJ. Time-restricted feeding for the prevention of cardiometabolic diseases in high-stress occupations: a mechanistic review. Nutr Rev 2019.
488. Esteban JPG, Rein LE, Szabo Aniko, Gawrieh S, Saeian K. Not Just What, but also When You Eat: Analyzing the Impact of Meal Timing Patterns on Non-Alcoholic Fatty Liver Disease. Hepatology 2016;64:S17A.
489. Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res 2017;113:1074-86.
490. Magkos F. Metabolically healthy obesity: what's in a name? The American Journal of Clinical Nutrition 2019;110:533-9.
491. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66:569-80.
492. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 2017;66:1727-38.
493. Caussy C, Ajmera VH, Puri P, et al. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut 2019;68:1884-92.
494. Caussy C, Tripathi A, Humphrey G, et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nature Communications 2019;10:1406.
495. Wester V. Glucocorticoids and Obesity. 2018.
496. Eslam M, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. The Lancet 2019;394:2131-3.
497. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394:2184-96.
498. Siddiqui MS, Van Natta ML, Connelly MA, et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. Journal of hepatology 2020;72:25-33.
499. Security. Cff. Taxes, Inequality and Obesity. University of Reading Consulted on 18th of December 2019.